| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/27/2009 | US7482354 Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
| 01/27/2009 | US7482353 Compositions and methods pertaining to PNA synthons and oligomers comprising a universal base |
| 01/27/2009 | US7482352 Such as N6-[6-(2-dimethylaminoethylamino)-4-methylsulfanyl-[1,3,5]triazin-2-yl]-2-methylquinoline-4,6-diamine, which stabilizes DNA in G-quadruplex structures (guanine tetrads); anticancer agents |
| 01/27/2009 | US7482350 4,5-disubstituted-2-aryl pyrimidines |
| 01/27/2009 | US7482349 And beta-amyloid formation; Alzheimer's Disease; 2-amino-5-(4-fluoro-3-pyrimidin-5-ylphenyl)-5-(4-methoxy-3-methylphenyl)-3-methyl-3,5- dihydro-4H-imidazol-4-one |
| 01/27/2009 | US7482348 Piperazinyl substituted cyclohexane-1,4-diamines |
| 01/27/2009 | US7482347 CCR-3 receptor antagonists; inflammatory or allergic condition such as asthma or obstructive airway disease; 1-[1-(3,5-Dimethylisoxazole-4-sulfonyl)-piperdin-4-yl-methyl]-4-(4-fluorobenzyl)-piperazine; 1-(4-Fluorobenzyl)-4-(4-piperidinylmethyl) piperazine intermediate and a sulfonyl halide reactant |
| 01/27/2009 | US7482346 Carboxylation of the alkylpiperazine; amidation of the carbamate-ester; cannabinoid and vanilloid receptor antagonists |
| 01/27/2009 | US7482345 P38 kinase inhibiting agents |
| 01/27/2009 | US7482344 5-substituted arylmethylidenyl (thio)xanthenes; hypotensive agents, antiinflammatory agents, antiarthritic agents; congestive heart failure |
| 01/27/2009 | US7482343 Mitotic kinesin KSP inhibitors; antiproliferative agents; 2-methylpyrimidin-4-ones |
| 01/27/2009 | US7482342 Indazolecarboxamide derivatives, preparation and use thereof as CDK1, CDK2 and CDK4 inhibitors |
| 01/27/2009 | US7482341 N-(pyridin-2-yl)-benzenesulfonamides; antidiabetic agents for Type II Diabetes; obesity; 11beta-hydroxysteroid dehydrogenase inhibitors |
| 01/27/2009 | US7482340 Pyridine derivatives useful for inhibiting sodium/calcium exchange system |
| 01/27/2009 | US7482339 Cannabinoid receptor agonists; antipruritic agents, analgesics, bronchodilator agents |
| 01/27/2009 | US7482338 Non-amide nonanes |
| 01/27/2009 | US7482337 Antidiabetic agents; dietetics; antiarthritic agents; osteoporosis; angiotensin converting enzyme inhibitor |
| 01/27/2009 | US7482336 Aminocyclohexanes as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
| 01/27/2009 | US7482335 Cyclic amide derivative as monocyte chemotactic protein modulator; prevention and treatment of rheumatoid arthritis, multiple sclerosis, atherosclerosis and asthma; antiinflammatory agents |
| 01/27/2009 | US7482334 1-Alpha, 3-beta, 17-beta-trihydroxy-4 alpha-fluoroandrost-5-ene; cystic fibrosis, neutropenia |
| 01/27/2009 | US7482330 3-(4-Ethylbenzyl)-5-( beta -D-glucopyranosyl)-1H-indole; antidiabetic agents; insulin resistance |
| 01/27/2009 | US7482320 Modulation of smooth muscle cell proliferation |
| 01/27/2009 | US7482319 delivery of enzyme, a pharmaceutical agent, a plasmid, a polynucleotide, a polypeptide, a sensor to an organism, tissue or cell by incorporting into a vault like particle such as polypeptide, linked to MVP, VPARP, a portion of VPARP, or a modified MVP, VPARP; adminstering |
| 01/27/2009 | US7482149 Inhibition of SARS coronavirus infection with clinically approved antiviral drugs |
| 01/27/2009 | US7482138 PAK5-related compositions and methods |
| 01/27/2009 | US7482137 glycosylation endproducts of polyketides, glycoproteins or polyketide-peptide substrates with microbial glycosyltransferases |
| 01/27/2009 | US7482134 Signals and molecular species involved in senescence |
| 01/27/2009 | US7482032 For preventing various kinds of damage resulting from oxidation and exposure to ultraviolet light; for use in food, cosmetics and medicine |
| 01/27/2009 | US7482028 Plant derived or derivable material with appetite suppressing activity |
| 01/27/2009 | US7482026 Compositions and methods directed towards sore muscles and joints |
| 01/27/2009 | US7482024 highly dispersible mixture of drugs and dipeptides or tripeptides, in the form of liquids, aerosols or powders, administered by inhalation |
| 01/27/2009 | US7482022 Palatable chewable tablet |
| 01/27/2009 | US7481998 Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |
| 01/27/2009 | US7481995 Aerosol composition |
| 01/27/2009 | CA2489407C Lasofoxifene tablet and its coating |
| 01/27/2009 | CA2474701C Preparation of biodegradeable microparticles containing a biologically active agent |
| 01/27/2009 | CA2438168C Modulated release particles for aerosol delivery |
| 01/27/2009 | CA2430696C Phenylethenyl or phenylethinyl derivatives as glutamate receptor antagonists |
| 01/27/2009 | CA2418167C Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses |
| 01/27/2009 | CA2416403C A medicinal aerosol formulation |
| 01/27/2009 | CA2415442C Novel .beta. crystalline form of perindopril tert-butylamine salt, preparation method, and pharmaceutical compositions containing same |
| 01/27/2009 | CA2408941C New process for the preparation of vinyl-pyrrolidinone cephalosporine derivatives |
| 01/27/2009 | CA2399856C Antibiotic composition with inhibitor |
| 01/27/2009 | CA2395226C Devices for the delivery of drugs having antiprogestinic properties |
| 01/27/2009 | CA2391871C Anti-inflammatory oxo derivatives and hydroxy derivatives of pyrrolizines, and their pharmaceutical use |
| 01/27/2009 | CA2389280C Triazoles as farnesyl transferase inhibitors |
| 01/27/2009 | CA2388646C Methods and compositions utilizing quinazolinones |
| 01/27/2009 | CA2380757C Pharmaceutical agent comprising a benzamide derivative as active ingredient |
| 01/27/2009 | CA2378803C Vitamin d3 analogs |
| 01/27/2009 | CA2377226C Benzimidazole compounds and medicaments comprising the same |
| 01/27/2009 | CA2377126C Thiazole and oxazole derivatives and their pharmaceutical use |
| 01/27/2009 | CA2362499C Combinations of formoterol and mometasone furoate for asthma |
| 01/27/2009 | CA2361605C Pyrimidine-2,4,6-triones as inhibitors of matrix metalloproteinases |
| 01/27/2009 | CA2360248C Combinations of formoterol and a tiotropium salt |
| 01/27/2009 | CA2355243C Novel 2-(n-cyanoimino)thiazolidin-4-one derivatives |
| 01/27/2009 | CA2350894C Methods for preparing coated drug particles and pharmaceutical formulations thereof |
| 01/27/2009 | CA2348451C Dosage forms containing taste masked active agents |
| 01/27/2009 | CA2346644C Method for preventing xenograft transplant rejection using photodynamic therapy |
| 01/27/2009 | CA2338066C Treatment of dyskinesia |
| 01/27/2009 | CA2335115C Fused azepinone cyclin dependent kinase inhibitors |
| 01/27/2009 | CA2334355C Prostaglandin derivatives |
| 01/27/2009 | CA2332038C Novel pharmaceutical composition for use in emergency treatment and preparation method thereof |
| 01/27/2009 | CA2296669C Nutritional composition for the treatment of pressure ulcers |
| 01/27/2009 | CA2294586C Homoserine lactones biofilm regulating compounds and their methods of use |
| 01/27/2009 | CA2290520C Inhibition of p38 kinase activity by aryl ureas |
| 01/27/2009 | CA2283071C Serine proteinase inhibitory activity by hydrophobic tetracycline |
| 01/27/2009 | CA2265198C Method of producing a nicotine medicament and a medicament made by the method |
| 01/27/2009 | CA2264028C A stable ointment containing acetyl salicylic acid |
| 01/27/2009 | CA2247443C Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to ppar-gamma |
| 01/27/2009 | CA2235372C Method for treating ischemic tissue |
| 01/27/2009 | CA2225278C Recombinant mva virus, and the use thereof |
| 01/27/2009 | CA2221513C Fluorochemical liquid augmented cryosurgery |
| 01/27/2009 | CA2197319C Lipid analogs for treating viral infections |
| 01/27/2009 | CA2176298C A single high dose fluoroquinolone treatment |
| 01/27/2009 | CA2135644C Mutated steroid hormone receptors, methods for their use and molecular switch for gene therapy |
| 01/26/2009 | CA2637979A1 Treatment of cardiovascular disease in mexican americans using nebivolol |
| 01/22/2009 | WO2009012430A1 Sulfonamides as trpm8 modulators |
| 01/22/2009 | WO2009012425A2 Compositions including leukotriene antagonists and nsaids and methods of using the same |
| 01/22/2009 | WO2009012421A1 Cyclic amine substituted pyrimidinediamines as pkc inhibitors |
| 01/22/2009 | WO2009012393A1 Pharmaceutical composition comprising a proton pump inhibitor and protein component |
| 01/22/2009 | WO2009012376A1 Compositions and methods for skin care |
| 01/22/2009 | WO2009012357A2 Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof |
| 01/22/2009 | WO2009012312A1 Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
| 01/22/2009 | WO2009012280A2 Benzimidazole poly(adp-ribose)polymerase inhibitors |
| 01/22/2009 | WO2009012277A1 Method for modulating gpr119 g protein-coupled receptor and selected compounds |
| 01/22/2009 | WO2009012275A1 Pyridone gpr119 g protein-coupled receptor agonists |
| 01/22/2009 | WO2009012262A1 Protein kinase modulating compounds and methods for making and using them |
| 01/22/2009 | WO2009012259A1 Pentafluorosulfanyl-substituted piperazinylpiperidine derivatives as chemokine receptor antagonists |
| 01/22/2009 | WO2009012252A1 Aminoalkylazole derivatives as histamine-3 antagonists |
| 01/22/2009 | WO2009012242A2 Sodium channel inhibitors |
| 01/22/2009 | WO2009012241A1 Sodium channel inhibitors |
| 01/22/2009 | WO2009012223A1 Compositions for the treatment of metabolic disorders |
| 01/22/2009 | WO2009012221A1 Heterocyclic modulators of cannabinoid receptors |
| 01/22/2009 | WO2009012211A1 Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds |
| 01/22/2009 | WO2009012205A1 Inhibitors of beta amyloid production |
| 01/22/2009 | WO2009012125A1 Compounds and methods for modulating fxr |
| 01/22/2009 | WO2009012096A2 Improved therapeutic methods and compositions comprising chroman ring compounds |
| 01/22/2009 | WO2009012091A1 Methods for repelling arthropods using isolongifolenone and/or isologifolenone analogs |
| 01/22/2009 | WO2009012082A1 Methods for treating anxiety |
| 01/22/2009 | WO2009012075A1 Use of iop-lowering agents for treating primary and secondary forms of glaucoma |